|Articles|June 16, 2020
Pratia and KFGN Join Forces
Advertisement
Pratia Inc has claimed 40% shares in KFGN, with an overall investment plan that assumes increased shareholding up to a clear majority position in the upcoming years. Dr. Ole Dammann will continue his leadership as CEO of KFGN. Additionally, as a Board Member of Pratia, he will support international growth of Site Network.
For more information, click
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Breaking the Efficacy Ceiling in IBD and Beyond
2
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
5